Prophylactic Role of Intra-Vitreal Bevacizumab(Avastin) in Diabetic Patients Under Going Phacoemulcification
Objectives: To study the effect of pre-operative intra-vitreal Avastin (bevacizumab) in diabetic patients undergoing phacoemulcification on central macular thickness and best corrected visual acuity.
Methods: A randomized controlled trial was conducted which included 42 patients (N=42). Group A and B had 21 patients each. Group A patients received injection Avastin (Bevacizumab) one week before phacoemulcification and Group B patient underwent phacoemulcification alone. Pre-operative best corrected visual acuity (BCVA) and central macular thickness (CMT) was recorded before giving intravitreal bevacizumab. Post-operative BCVA and CMT was noted 4 weeks after the surgery.
Results: The difference in final visual acuity between Group A and B was not statistically significant. Change
in CMT from pre-operative value was not significant in study population (p=0.364), but was statistically significant in both groups individually (p=0.029, 0.001 respectively).
Conclusion: Our study concludes that cataract surgery along with prophylacticintra-vitreal Avastin
(bevacizumab) may contribute in short term improvement of macular thickness, but does not have any
statistical significant effect on final BCVA.
Key Words: Bevacizumab (Avastin), Phacoemulcification, Best Corrected Visual Acuity, Centeral Macular Thickness (CMT)
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments firstname.lastname@example.org